Document is current
Any future updates will be listed below
-
Authors
Kumar, Amit
Kapoor, Akhil
Noronha, Vanita
Patil, Vijay
Menon, Nandini
Singh, Ajay Kumar
Joshi, Amit
Janu, Amit
Kaushal, Rajiv Kumar
Pai, Trupti
Chougule, Anuradha
Shetty, Omshree
Prabhash, Kumar
- License Information
-
More Information
Article History
Received: 18 December 2023
Revised: 27 February 2024
Accepted: 6 March 2024
First Online: 1 May 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Noronha reports grants from Dr. Reddy’s Laboratories Ðnc, grants from. Amgen, grants from Sanofi Aventis, outside the submitted work. Dr. Prabhash reports grants from Biocon Ltd, grants from Dr. Reddy’s Laboratories Inc, grants from Fresenius Kabi India Pvt Ltd, grants from Alkem Laboratories, grants from Natco Pharma Ltd, grants from BDR Pharmaceutics Intl Pvt Ltd, grants from Roche Holding AG, outside the submitted work. None of the other authors have anything to declare that may be considered as potential competing interest.
: The lung cancer audit is an Institutional Ethics Committee (IEC) approved observational protocol and is registered with the Clinical Trials Registry India (registration number: CTRI/2013/01/003335). The study was conducted according to ethical guidelines established by the Declaration of Helsinki and other guidelines like Good Clinical Practice Guidelines and those established by the Indian Council of Medical Research (ICMR).
